Cancer Research and Treatment

Case Report

Possible Ribociclib-Associated Focal Nodular Hyperplasia–Like Lesion Mimicking Liver Metastasis in a Chemotherapy-Naïve Patient: First Case Report: Ece Ulukal Karancı, Armağan Günal, Ahmet Şükrü Alparslan, Banu Öztürk; Received February 22, 2026 Accepted July 11, 2026 Published online July 15, 2026; DOI: https://doi.org/10.4143/crt.2026.0178 [Accepted]

Abstract PDF: Hepatic focal nodular hyperplasia (FNH)–like lesions mimicking metastasis have been reported as rare complications of cytotoxic chemotherapy, but they have not previously been described in association with CDK4/6 inhibitors alone. We present the case of a 32-year-old chemotherapy-naïve woman with de novo hormone receptor (HR)–positive/HER2-negative metastatic breast cancer who was treated with first-line ribociclib and letrozole. After four cycles, imaging revealed a complete response of her bone metastases alongside a newly developed 5.5-cm hepatic lesion suspicious for visceral progression. Liver function tests remained normal. Two ultrasound-guided percutaneous core biopsies, performed three months apart and directly targeting the lesion, confirmed a benign FNH-like lesion without evidence of malignancy. Ribociclib was continued without modification; at last follow-up the patient remained in sustained complete oncologic response, with the hepatic lesion stable in size and no biochemical or clinical evidence of hepatic dysfunction. To our knowledge, this appears to be the first reported case of an FNH-like hepatic lesion temporally associated with ribociclib in a patient who had not received prior cytotoxic chemotherapy. The principal clinical message is that newly detected hepatic lesions arising during otherwise effective targeted therapy do not necessarily reflect disease progression, and that, in radiologically discordant cases, histopathologic confirmation may be required to avoid premature discontinuation or switching of effective treatment.

435 View
33 Download

Original Articles

The Role of Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer with Microsatellite Instability-High or DNA Mismatch Repair Deficiencies: A Multicenter Pooled Analysis (KCSG-CO24-03): Joon Young Hur, Hana Kim, Soon Il Lee, Se Jun Park, Jina Yun, Seok Yun Kang, Cheolsik Kim, Seung-Hoon Beom, Hyeyeong Kim, So-Yeon Jeon, Jaemin Jo, Yongho Noh, Jong Gwang Kim, Hyun Jin Bang; Received February 14, 2026 Accepted May 27, 2026 Published online May 29, 2026; DOI: https://doi.org/10.4143/crt.2026.0156 [Accepted]

Abstract PDF: Purpose
The benefit of adjuvant chemotherapy (CTx) for high-risk stage II microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colon cancer remains controversial with discordant international guidelines. This study evaluated outcomes comparing adjuvant chemotherapy group versus surgery only group.
Materials and Methods
This multicenter retrospective analysis included 192 patients with high-risk stage II MSI-H/dMMR colon cancer who underwent curative resection between 2010 and 2020. High-risk features included pT4, grade 3-4, lymphovascular invasion, bowel obstruction/perforation, perineural invasion (PNI), inadequate lymph node sampling (<12), or close margins. The primary endpoint was 5-year relapse-free survival (RFS), excluding second primary malignancies to isolate antitumor efficacy.
Results
Of 192 patients, 128 (66.7%) received adjuvant CTx and 64 (33.3%) underwent observation (median follow-up 60.5 months). Five-year RFS (94.0% vs. 83.7%; p=0.001) and OS (98.3% vs. 89.0%; p=0.001) were significantly higher with adjuvant CTx. Multivariate analysis confirmed adjuvant CTx as an independent predictor for RFS (HR 0.249, 95% CI 0.109-0.571; p=0.001) and OS (HR 0.155, 95% CI 0.051-0.470; p=0.001). PNI was also identified as a significant independent predictor of RFS (HR, 3.581; 95% CI, 1.529 to 8.387; p=0.003) and OS (HR, 4.968; 95% CI, 1.654 to 14.930; p=0.004). CTx-related toxicities were clinically manageable, and no treatment-related deaths were reported.
Conclusion
Adjuvant CTx significantly improves RFS and OS in high-risk stage II MSI-H/dMMR colon cancer, particularly in pT4 and PNI patients. These findings provide evidence to bridge NCCN and ESMO guideline discrepancies, supporting risk-stratified adjuvant CTx in this population.

937 View
53 Download

Platinum and 5-Fluorouracil Salvage Therapy for Severe Liver Crisis in Metastatic Breast Cancer: Efficacy and Analysis of Prognostic Factors: I-Wei Ho, Jiun-I Lai, Chun-Yu Liu, Wei-Chi Lin, Muh-Hwa Yang, Ling-Ming Tseng, Ta-Chung Chao; Received November 18, 2025 Accepted December 28, 2025 Published online December 29, 2025; DOI: https://doi.org/10.4143/crt.2025.1262 [Epub ahead of print]

Abstract PDF PubReader ePub: Purpose
Metastatic breast cancer (MBC) with severe hepatic dysfunction due to liver crisis presents a significant treatment challenge, as conventional chemotherapy often requires dose modifications, leading to reduced efficacy. The combination of platinum, 5-fluorouracil, and folinate (PFL) offers a rational treatment strategy. This study evaluates the efficacy and safety of PFL in MBC patients with liver crisis and explores predictive markers for treatment response.
Materials and Methods
This retrospective cohort study, conducted at Taipei Veterans General Hospital, Taiwan, included 44 MBC patients with bilirubin ≥ 3 mg/dL treated between January 2015 and June 2024. Outcomes included bilirubin response rate (≥ 50% reduction from baseline), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events. The area under the curve analysis was used to determine the optimal cutoff for liver function assessment models, and Cox regression identified independent prognostic factors.
Results
Among the 44 patients, 47.7% achieved a bilirubin response within a median of 19 days. Overall, the median PFS and OS were 1.4 and 1.9 months, respectively, but improved to 4.6 and 7.8 months in those achieving bilirubin response. The objective response rate was 22.7%, and the disease control rate was 29.5%. A fibrosis-4 (FIB-4) score < 9.1 predicted a 65% bilirubin response rate, while FIB-4 > 9.1 was also an independent predictor of OS. Grade 3 adverse events occurred in 36.4% of patients.
Conclusion
The PFL regimen is effective in MBC patients with severe liver crisis with hyperbilirubinemia. A FIB-4 score < 9.1 may serve as a potential prognostic factor for bilirubin response and is associated with improved survival outcomes.

1,228 View
75 Download

Association between FGFR2b Positivity and Survival Outcomes of Patients with Gastric Cancer Treated with First-Line Nivolumab Plus Chemotherapy: Hyung-Don Kim, Heonwoo Lee, Hyungeun Lee, Meesun Moon, Jaewon Hyung, Jungeun Ma, Young Soo Park, Min-Hee Ryu; Received June 6, 2025 Accepted November 22, 2025 Published online November 24, 2025; DOI: https://doi.org/10.4143/crt.2025.598 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Purpose
Fibroblast growth factor receptor 2b (FGFR2b) is a promising therapeutic target in gastric cancer; however, its clinical relevance in immune checkpoint inhibitor (ICI)-based chemotherapy remains unclear. Therefore, this study aims to evaluate the expression pattern and predictive value of FGFR2b in patients undergoing first-line nivolumab plus chemotherapy.
Materials and Methods
This single-center study included 503 patients diagnosed with gastric cancer. Among them, 296 underwent nivolumab-chemotherapy, while 207 underwent chemotherapy alone. FGFR2b expression was assessed via immunohistochemistry using samples collected after mid-2022. FGFR2b positivity was defined as membranous staining intensity of 2+/3+ in ≥ 1% of tumor cells, with ≥ 10% as overexpression, and 1–9% as low expression.
Results
FGFR2b overexpression and positivity were identified in 9.3% and 16.7% of cases, respectively. Discordance between paired biopsy and surgical samples was observed (20.0% and 40.0% for overexpression and positivity, respectively), indicating marked intratumoral heterogeneity. Among patients who underwent nivolumab-chemotherapy, FGFR2b overexpression and low expression were associated with favorable survival trends compared to those of FGFR2b-negative cases. These associations were not observed in patients treated with chemotherapy alone. Compared to chemotherapy alone, nivolumab-chemotherapy was associated with a greater survival benefit in patients with FGFR2b positivity. Multivariate interaction analyses revealed a significant interaction between FGFR2b expression and nivolumab-based chemotherapy.
Conclusion
FGFR2b expression exhibits substantial intratumoral heterogeneity in gastric cancer and may be linked to favorable outcomes in patients undergoing first-line ICI plus chemotherapy. Therefore, future studies should validate this finding, along with mechanistic investigations.

Citations

Citations to this article as recorded by

Patient-derived organoids in gastric cancer: bridging the tumor microenvironment to functional precision oncology
Ji Ma, Xinyang Liu, Hongtao Xu, Chuan Jiang
Frontiers in Bioengineering and Biotechnology.2026;[Epub] CrossRef

1,273 View
80 Download
1 Crossref

Chemotherapy-Free Salvage Therapy with Rituximab, Lenalidomide, and Poseltinib in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Multi-center, Phase II Study: Dong Hyun Kim, Sanyeowool An, Hongyul Ahn, Han Song, Ka-Won Kang, Sang Eun Yoon, Seok Jin Kim, Hyo Jung Kim, Youngil Koh, Deok-Hwan Yang, Consortium for Improving Survival of Lymphoma (CISL); Received September 6, 2025 Accepted November 11, 2025 Published online November 12, 2025; DOI: https://doi.org/10.4143/crt.2025.977 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
Relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL) is an aggressive malignancy for which salvage chemotherapy has limited efficacy. We conducted an investigator-initiated, single-arm, multicenter phase II trial to evaluate the efficacy and safety of a chemotherapy-free salvage regimen comprising rituximab, lenalidomide, and poseltinib (R2P) in patients with R/R PCNSL.
Materials and Methods
The R2P regimen consisted of two phases: six cycles of induction with rituximab, lenalidomide, and poseltinib, followed by three cycles of consolidation with lenalidomide and poseltinib. The primary endpoints were complete response rate (CRR) and overall response rate (ORR). Secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS).
Results
A total of 10 patients were enrolled (one withdrew before cycle 1; nine were evaluable for efficacy). The median age was 70 years (range, 53 to 75 years), and all had received methotrexate-based first-line chemotherapy. The ORR was 55.6%, and the CRR was 33.3%. The median PFS was 5.6 months, and the median OS was not reached. Next-generation sequencing was performed in four patients (three responders and one non-responder). CD79B missense mutations were identified in all three responders. A total of 11 adverse events (AEs) were observed in six patients. The most common AE was neutropenia (30.0%). The only grade ≥ 3 AE was a single case of grade 3 neutropenia. No dose modifications were required due to toxicity.
Conclusion
Poseltinib in combination with lenalidomide and rituximab showed activity in patients with R/R PCNSL, warranting further investigation in larger studies.

2,008 View
161 Download

RMRP-Induced Chemo-resistance in Relapsed and Refractory Acute Myeloid Leukemia via Mitochondrial Dysfunction: Yijing Zhao, Hanfei Guo, Yalan Zhou, Li-Ting Niu, Na Wu; Received March 11, 2025 Accepted August 6, 2025 Published online August 7, 2025; DOI: https://doi.org/10.4143/crt.2025.281 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
Relapsed and refractory acute myeloid leukemia (R/R AML) has a poor prognosis due to chemotherapy resistance. Mitochondrial dysfunction contributes to this resistance, but the role of the RNA component of mitochondrial RNA processing endoribonuclease (RMRP) in R/R AML remains unclear.
Materials and Methods
Mass spectrometry identified molecules linked to chemoresistance in AML. The role of RMRP was examined by assessing its impact on mitochondrial transfer in the AML bone marrow microenvironment. Transmission electron microscopy and western blotting were used to study mitochondrial function and autophagy in RMRP-knockdown AML cells.
Results
RMRP was overexpressed in R/R AML, and its silencing sensitized AML cells to chemotherapy drugs. RMRP knockdown reduced mitochondrial respiratory capacity, mitochondrial DNA copy numbers, and mitochondrial gene transcription. It also led to altered mitophagy markers and increased mitochondrial DNA methylation. Immunoprecipitation revealed RMRP–telomerase reverse transcriptase complex formation, suggesting a role in post-transcriptional regulation of mitochondrial function and reactive oxygen species production.
Conclusion
High RMRP expression in R/R AML is linked to mitochondrial dysfunction and chemotherapy resistance, providing new insights into potential therapeutic strategies to overcome drug resistance in this disease.

1,908 View
109 Download

Gastrointestinal cancer

Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4): Yoon-Koo Kang, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Sun Young Rha, Keun-Wook Lee, Ik Joo Chung, Sung Yong Oh, Sun Jin Sym, Won Ki Kang, Jong Gwang Kim, Byoung Yong Shim, In-Ho Kim, Jin Young Kim, Eun-Kee Song, Hyo-Jin Lee, Seok Yun Kang, Dong-Hoe Koo, So Yeon Oh; Cancer Res Treat. 2026;58(3):846-859. Published online July 2, 2025; DOI: https://doi.org/10.4143/crt.2024.913

Abstract PDF Supplementary Material PubReader ePub

Purpose
We report the safety and efficacy of nivolumab+chemotherapy for first-line treatment of advanced or recurrent gastric or gastroesophageal junction cancer in the Korean subpopulation of the ATTRACTION-4 clinical trial.
Materials and Methods
ATTRACTION-4 (NCT02746796) was a double-blind, randomized, placebo-controlled clinical trial of patients aged ≥ 20 years with histologically confirmed unresectable advanced or recurrent gastric or gastroesophageal junction cancer. Patients received nivolumab or placebo, both combined with physician-choice chemotherapy (oxaliplatin plus oral S-1 [tegafur–gimeracil–oteracil] [SOX] or oral capecitabine [CAPOX]).
Results
Overall, 464 patients were initially screened in Korea and 291 were randomized to nivolumab+chemotherapy (total/SOX/CAPOX: 148/66/82 patients) or placebo+chemotherapy (total/SOX/CAPOX: 143/61/82 patients). Centrally assessed progression-free survival (median, 14.75 vs. 8.34 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.39 to 0.73; p < 0.001), overall survival (19.7 vs. 14.9 months; HR, 0.78; 95% CI, 0.60 to 1.02; p=0.065), overall response rate (54.7% vs. 47.6%), and duration of response (16.03 vs. 9.86 months) favored nivolumab+chemotherapy vs. placebo+chemotherapy. Grade ≥ 3 treatment-related adverse events (TRAEs) (56.1% vs. 44.1%), and any-grade endocrine (9.5% vs. 4.2%), hepatic (23.0% vs. 14.7%), hypersensitivity and infusion reactions (15.5% vs. 7.0%), renal (4.1% vs. 0.7%), and skin (44.6% vs. 23.1%) TRAEs tended to be more frequent in the nivolumab+chemotherapy group.
Conclusion
These findings demonstrate the clinical benefit of nivolumab combined with chemotherapy (either SOX or CAPOX) for first-line treatment of gastric cancer/gastroesophageal junction cancer in Korean patients.

Citations

Citations to this article as recorded by

Claudin18.2 promote gastric cancer proliferation by activating MCM2/5
Bowen Zheng, Miao Fu, Fanzhuoran Lou, Yuting He, Lingying Zhao, Xintian Huang, Xiaowen Xie, Weijuan Tan, Quan Chen, Wenqing Zhang, Yongxiang Hong, Kaiyi Rong, Yuyan Lu, Ping Zhan, Jingke Tu, Huibo Shi, Tianhui Hu, Li Xiao
Scientific Reports.2026;[Epub] CrossRef
Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
Yohei Iimura, Junichi Higuchi, Akimitsu Maeda, Kazuhiro Shimomura, Hirotoshi Iihara, Hironori Fujii, Takuya Iwamoto, Yoshitaka Saito, Hisanaga Nomura, Keiko Komori, Hidenori Tokuda, Ryuta Urakawa, Tatsuya Sumiya, Ryosuke Yanai, Mariko Kono, Masaki Ihira,
International Journal of Clinical Oncology.2026; 31(6): 957. CrossRef
Overcoming diagnostic pitfalls in primary gastric squamous cell carcinoma: the imperative of adequate sampling in an elderly female patient, case report
Wanhui Dong, Li Cheng, Jing Xu, Sheng Xu, Yuling Yin, Qingming Sun, Yong Wu, Yuling Leng
Frontiers in Oncology.2025;[Epub] CrossRef
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup—Combined Efficacy and
Keun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, Sun Jin Sym, Byoung Yong Shim, Seok Yun Kang, In-Ho Kim, Jwa Hoon Kim, Hong Jae Chon, Sang-Hee Cho, Eun-Kee Song, Do-Youn Oh, Jin-Soo Kim, Young Iee Park, Won Ki Kang, Hyung-Don Kim, Janise Lee, Miri Yi, Min-H
Cancer Research and Treatment.2025;[Epub] CrossRef

5,925 View
354 Download
4 Crossref

Breast cancer

Adjuvant Chemotherapy in Breast Cancer after Neoadjuvant Therapy: Essential or Optional?: Di Zhang, Luo Yang, Yuan Zheng, Qi Zhou; Cancer Res Treat. 2026;58(1):208-220. Published online April 24, 2025; DOI: https://doi.org/10.4143/crt.2024.1254

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the impact of postoperative adjuvant chemotherapy (AC) on survival outcomes in breast cancer (BC) patients who have already undergone neoadjuvant chemotherapy (NAC) followed by surgery.
Materials and Methods
Data from a population-based cohort (2010-2020) were analyzed for BC patients treated with NAC and surgery. Univariate and multivariate Cox regression identified prognostic factors for overall survival (OS), and a nomogram was developed and validated. Personalized scores from the nomogram were used for risk stratification to assess the effect of postoperative AC.
Results
A total of 15,921 BC patients were analyzed, with 11,144 in the training cohort and 4,777 in the validation cohort. The key prognostic indicators for OS included age, race, marital status, histological grade, BC subtype, T category, N category, type of surgery, and response to NAC (all p < 0.05). The nomogram effectively predicted individualized OS rates and stratified patients into various risk categories. Postoperative AC was found to significantly enhance OS in the high-risk subgroup (p=0.011 in the training cohort, p=0.012 in the overall population). However, for the low-risk subgroup, there was no significant survival benefit from postoperative AC (p=0.130 for the training cohort, p=0.588 for the overall population), suggesting that some patients might safely forgo unnecessary postoperative AC.
Conclusion
This study efficiently differentiates between varying levels of risk, enabling clinicians to identify patients unlikely to benefit from postoperative AC and thus reduce the likelihood of overtreatment.

Citations

Citations to this article as recorded by

Advances in nano-drug delivery systems for targeting therapy of breast cancer
Yi Zhao, Yamin Cui, Ze Zhao
Journal of Pharmacy and Pharmacology.2026;[Epub] CrossRef
An Exploratory Study on the Interrelation of Breast Cancer Molecular Phenotypes with Breast Cancer-Associated Adipose Tissues (BCAATs), Neoadjuvant, and Adjuvant Therapies: A Focus on Prognosis and Survival
Mihaela Maria Pasca Fenesan, Razvan George Bogdan, Andrei Alexandru Cosma, Vlad Vornicu, Eugen Melnic, Diana Veronica Radu, Patricia Baran, Zorin Crainiceanu, Rodica Elena Heredea, Olga Cernetchi, Anca Maria Cimpean
Medical Sciences.2026; 14(3): 403. CrossRef

3,389 View
79 Download
2 Web of Science
2 Crossref

General

Association of Physical Activity with Dementia Risk in Cancer Survivors: A Korean Nationwide Cohort Study: Su Kyoung Lee, Minji Han, Sangwoo Park, Sun Jae Park, Jihun Song, Hye Jun Kim, Jaewon Kim, Hyeokjong Lee, Hyun-Young Shin, Kyae Hyung Kim, Sang Min Park; Cancer Res Treat. 2026;58(1):48-60. Published online March 27, 2025; DOI: https://doi.org/10.4143/crt.2024.901

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the impact of physical activity on dementia risk among cancer survivors in South Korea.
Materials and Methods
This retrospective, population-based cohort study included 344,152 cancer survivors identified from the National Health Insurance Service database in South Korea. The mean follow-up time was 5.81 years. Different levels of physical activity post-cancer diagnosis, ranging from inactive to highly active, were assessed. The primary outcome was the incidence of overall dementia, Alzheimer’s disease, and vascular dementia. Secondary outcomes included dementia risk stratified by cancer type and treatment (chemotherapy and radiation).
Results
Of the total participants, 24,363 (7.08%) developed dementia. The risk of overall dementia decreased sequentially across the exercise groups compared to the inactive group: insufficiently active (adjusted hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.86 to 0.92), active (adjusted HR, 0.85; 95% CI, 0.83 to 0.88), and highly active (adjusted HR, 0.79; 95% CI, 0.76 to 0.82). This inverse relationship between exercise and dementia risk was statistically significant across various cancer types and was consistent regardless of age, comorbidities, and whether or not excluding the first 1, 2 years.
Conclusion
Among cancer survivors in South Korea, increased physical activity post-diagnosis was associated with a significantly lower risk of dementia. These findings underscore the importance of promoting physical activity in cancer survivors for cognitive health.

Citations

Citations to this article as recorded by

Global mammographic asymmetry and short-term breast cancer risk by breast density: a nationwide screening cohort of 5.5 million women
Sangjun Lee, Soyeoun Kim
The Breast.2026; 86: 104708. CrossRef
Interval from Cancer Diagnosis to Depression Onset and Risk of Dementia in Cancer Survivors
Sangjun Lee, Soyeoun Kim
Cancer Epidemiology, Biomarkers & Prevention.2026; 35(8): 1329. CrossRef

4,212 View
156 Download
2 Web of Science
2 Crossref

Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial: Hyeon-Jong Kim, Hyunjin Bang, Hyun-Jung Shim, Jun Eul Hwang, Sang-Hee Cho, Ik-Joo Chung, Seung Ji Kang, Jong Gwang Kim, Seung-Hoon Beom, A-Yeung Jang, Joon Young Song, Woo Kyun Bae; Cancer Res Treat. 2026;58(1):61-70. Published online February 12, 2025; DOI: https://doi.org/10.4143/crt.2024.1083

Abstract PDF Supplementary Material PubReader ePub: Purpose
Current guidelines recommend vaccination at least 2 weeks before chemotherapy initiation to optimize the immune response despite limited evidence. Our previous study indicated no differences in short-term immune response for the 13-valent pneumococcal conjugate vaccine (PCV13) according to the vaccination timing. This study aims to investigate the long-term efficacy of PCV13 and clinical factors associated with the respective antibody response.
Materials and Methods
Patients with gastric or colorectal cancer who received adjuvant chemotherapy were enrolled and divided into two groups: vaccinated 2 weeks before chemotherapy (arm A) and vaccinated concurrently with chemotherapy (arm B). Serum samples were collected before vaccination and in one month, 3 years, and 5 years. Immune responses were measured using enzyme-linked immunosorbent assay and multiplex opsonophagocytosis assay.
Results
Including 63 patients, both groups showed an initial increase in the geometric mean titers of opsonophagocytic activity and the geometric mean concentrations of serotype-specific IgG levels after one month, followed by a decline at 3 and 5 years, particularly for serotypes 1, 14, 18C, and 19A. Despite the decline, global protection was maintained for 5 years, although global response decreased. The two arms did not show significant differences in immunogenicity nor in factors such as vaccination timing, age, cancer type, or chemotherapy regimen.
Conclusion
Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for > 5 years, and global response remained in over half of patients.

7,563 View
190 Download

Review Article

The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine: Jong Hyuk Yun, Yoon Young Choi, Jae-Ho Cheong; Cancer Res Treat. 2025;57(3):621-634. Published online January 23, 2025; DOI: https://doi.org/10.4143/crt.2024.1222

Abstract PDF PubReader ePub

Although gastric cancer remains a significant global health burden, its treatment strategies vary across different geographical regions, leading to distinct guidelines. In Asia, particularly in Korea, D2 gastrectomy followed by adjuvant chemotherapy has been established as the standard treatment for stage II/III gastric cancer based on landmark clinical trials. However, this “one-size-fits-all” approach requires refinement as emerging evidence suggests heterogeneous outcomes even within the same stage. This review discusses the evolving landscape of adjuvant treatment in gastric cancer, emphasizing the transition towards precision medicine. Recent molecular characterization of gastric cancer has revealed distinct subtypes with varying prognoses and chemotherapy responses, exemplified by the favorable outcomes of microsatellite instability–high tumors without adjuvant chemotherapy. Additionally, clinical factors including sub-stages within stage II/III, patient performance status, comorbidities, and personal preferences should be considered in treatment decisions. The integration of these molecular and clinical factors, along with shared decision-making between physicians and patients, represents a crucial step toward personalized treatment approaches. Looking ahead, the field is poised for further evolution with the emergence of immune checkpoint inhibitors, growing evidence for neoadjuvant chemotherapy in selected cases, and the potential of circulating tumor DNA as a biomarker for minimal residual disease. This comprehensive approach to treatment decision-making, considering both tumor biology and patient factors, will be essential for realizing precision medicine in gastric cancer care.

Citations

Citations to this article as recorded by

From Control to Conversion: Optimizing Systemic Therapy for Curative-Intent Conversion Surgery in Metastatic Gastric Cancer
Hye Sook Han, Sun Young Rha
Journal of Gastric Cancer.2026; 26(1): 146. CrossRef
Advances in Nano-Enabled Biosensing Technology for Gastric Cancer Diagnosis: Mechanistic Insights and Translational Perspectives
Anjali Yadav, Arzoo Saini, Neeraj Dilbaghi, Neelam Yadav
Critical Reviews in Analytical Chemistry.2026; : 1. CrossRef
A Nomogram Integrating HOXA9 Expression and Clinicopathological Factors for Predicting Postoperative Recurrence in Gastric Cancer: A Single-Center Retrospective Study
Jianze Weng, Jingwen Ying, Minming Xia, Yijie Xie
OncoTargets and Therapy.2026; Volume 19: 1. CrossRef
Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons
Yanyun Hong, Xiaodong Wang, Hang Yu, Xiaosun Liu, Chao Tang
Cellular Oncology.2026;[Epub] CrossRef
The Lymph Node Ratio as a Predictive Biomarker for Individualized Benefit from Adjuvant Chemotherapy in Gastric Cancer: A Retrospective Cohort and Causal Machine Learning Study
Wen-qi Hong, Ren-hao Hu, Xiao-hua Jiang, Shun Zhang
Journal of Gastrointestinal Cancer.2026;[Epub] CrossRef
Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy
Lhoucine Naanaai, Abdellah El Aissouq, Yassine El Allouche, Youssra Ech-Chahdi, Hicham Zaitan, Fouad Khalil
Beni-Suef University Journal of Basic and Applied Sciences.2026;[Epub] CrossRef
Preoperative albumin-bilirubin grade combined with sarcopenia predicts long-term outcomes after laparoscopic gastrectomy for advanced gastric cancer
Shuangshuang Hou, Yang Yu, Nanbo Li, Wenjing Yu, Zhiyuan Dai, He Li, Lianyi Guo, Jiajun Yin, Ju Wu
BMC Gastroenterology.2025;[Epub] CrossRef
Dynamic postoperative prognosis and follow-up optimization for gastric cancer patients after neoadjuvant therapy: a multicenter retrospective study
Qing Zhong, Zhi-Quan Zhang, Kai-Ning Ye, Min-Xian Zhuang, Yu-Qin Sun, Zhi-Xin Shang-Guan, Dong Wu, Cai-Ming Weng, Meng-Qi Xue, Tao-Yuan Qiu, Yi Li, Yu-Bin Ma, Fang-Hui Ding, Yong-Hong Wang, Shi-Chao Wu, Bao-Long Li, Wei Zhao, Ji-Yun Zhu, Jun-Hua Yu, Ju Wu
Gastric Cancer.2025; 28(6): 1260. CrossRef

10,402 View
282 Download
8 Web of Science
8 Crossref

Original Articles

Pediatric cancer

Prognostic Value of POST-Treatment Extent of Tumor (POSTTEXT) System in Patients with Hepatoblastoma: Hana Jeong, Hee Mang Yoon, Pyeong Hwa Kim, Ah Young Jung, Young Ah Cho, Jin Seong Lee, Kyung-Nam Koh, Jung-Man Namgoong; Cancer Res Treat. 2025;57(4):1198-1206. Published online January 20, 2025; DOI: https://doi.org/10.4143/crt.2024.600

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to assess prognostic values of the POST-Treatment Extent of tumor (POSTTEXT) system and clinical factors after neoadjuvant chemotherapy in hepatoblastoma patients and evaluate benefits of post-treatment imaging and clinical factors concomitant with Children’s Hepatic Tumors International Collaboration–Hepatoblastoma Stratification (CHIC-HS) system.
Materials and Methods
This single-center retrospective study of hepatoblastoma cases (2006-2022) included pediatric patients receiving ≥ 4 cycles of neoadjuvant chemotherapy, with pre- and post-treatment imaging and complete medical records. Clinical data included age, sex, and serum α-fetoprotein (AFP) levels. Cox regression analyses identified predictors of event-free survival (EFS). Time-dependent receiver operating characteristic curves assessed the predictive power of combining the CHIC-HS risk stratification with post-treatment factors. Inter-reader agreement was analyzed using weighted kappa.
Results
Among the 109 hepatoblastoma patients, 73 (mean age, 2.2±2.7 years) met the inclusion criteria. Prognostic factors for EFS included AFP levels after the fourth cycle of neoadjuvant chemotherapy (hazard ratio [HR], 1.233; 95% confidence interval [CI], 1.086 to 1.400; p=0.001), tumor size change ratio (HR, 0.654; 95% CI, 0.448 to 0.955; p=0.030), and POSTTEXT annotation factor M (HR, 5.209; 95% CI, 1.639 to 16.553; p=0.005). Incorporating AFP levels after the fourth cycle of neoadjuvant chemotherapy into the CHIC-HS improved predictive power (p=0.043). POSTTEXT system showed better inter-reader agreement than PRE-Treatment Extent of tumor (PRETEXT).
Conclusion
Predictors of EFS in hepatoblastoma include AFP levels after the fourth cycle of neoadjuvant chemotherapy, tumor size change ratio, and metastasis (POSTTEXT M). Combining AFP levels after the fourth cycle of neoadjuvant chemotherapy to the CHIC-HS improved the predictive ability.

Citations

Citations to this article as recorded by

Surgical management of biliary fistula following associating liver partition and portal vein ligation for staged hepatectomy in pediatric hepatoblastoma: a case report and literature review
Gang Shen, Yunpeng Zhai, Huashan Zhao, Rui Guo, Hongxiu Xu, Sai Huang, Shisong Zhang
Frontiers in Oncology.2025;[Epub] CrossRef

5,041 View
111 Download
1 Web of Science
1 Crossref

Head and Neck cancer

Phase II Trial of Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Combined with Pegteograstim for Unresectable, Locally Advanced Sinonasal Squamous Cell Carcinoma: KCSG HN18-07: Bhumsuk Keam, Ho Jung An, Seong Hoon Shin, Min Kyoung Kim, Jung Hae Cho, Seyoung Seo, Sung-Bae Kim; Cancer Res Treat. 2025;57(3):701-708. Published online December 16, 2024; DOI: https://doi.org/10.4143/crt.2024.1025

Abstract PDF Supplementary Material PubReader ePub

Purpose
The role of neoadjuvant chemotherapy in locally advanced sinonasal squamous cell carcinoma (SNSCC) has not been established prospectively. We conducted a phase II trial of neoadjuvant chemotherapy (NAC) with docetaxel/cisplatin/5-fluorouracil (TPF) in this population.
Materials and Methods
Eligible patients had unresectable, locally advanced SNSCC, defined as T3/4 category or potential compromise of critical organ function on surgery. Three TPF (docetaxel 75 mg/m2 and cisplatin 75 mg/m2 on day 1, 5-fluorouracil 1,000 mg/m2 on days 1-4 every 3 weeks) cycles were administered with prophylactic pegteograstim. The primary outcome was the objective response rate (ORR); the secondary outcomes included 2-year progression-free survival (PFS), eyeball preservation rate, and safety.
Results
Among 28 patients screened, 25 were evaluable for efficacy (one screen-failure; two evaluable for safety only). The confirmed ORR was 72.0%. The definitive post-NAC treatment comprised chemoradiotherapy (n=15) and surgery (n=10). With a median follow-up of 25.5 months, median PFS was not reached and the 2-year PFS rate was 60.4%. Response to NAC was related to prolonged PFS (p=0.038). No patient underwent eyeball exenteration at the data cutoff point. Treatment-related adverse events of grade ≥ 3 were neutropenia (48.1%) including febrile neutropenia (14.8%), followed by acute kidney injury (22.2%), nausea/vomiting (11.1%), anemia (7.4%), thrombocytopenia (7.4%), and enterocolitis (3.7%).
Conclusion
TPF NAC showed a promising efficacy and might help preserve critical structures in this population, which needs to be validated in a large prospective trial (KCT0003377).

Citations

Citations to this article as recorded by

Superselective intra-arterial chemoradiotherapy for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212
H. Tachibana, K. Matsuura, R. Onimaru, D. Yoshida, T. Kobayashi, T. Ueda, M. Nakahira, A. Ohkoshi, G. Omura, T. Mukaigawa, K. Katagiri, T. Asakage, H. Shinomiya, F. Ito, Y. Asada, T. Beppu, T. Fujii, Y. Hirayama, K. Tsukahara, Y. Saito, K. Ichikawa, H. Ue
ESMO Open.2026; 11(8): 108336. CrossRef

4,388 View
171 Download
1 Web of Science
1 Crossref

General

Which Chemotherapy-Related Terms Were Difficult for Cancer Patients, and Who Would Have the Most Difficulties?: Mangyeong Lee, Nayeon Kim, Ho-Young Kim, Ayoung Lee, Junghee Yoon, Juhee Cho; Cancer Res Treat. 2025;57(3):669-677. Published online December 3, 2024; DOI: https://doi.org/10.4143/crt.2024.485

Abstract PDF Supplementary Material PubReader ePub

Purpose
This cross-sectional study aimed to examine which chemotherapy (CTx) terms were most difficult to understand for cancer patients and identify vulnerable patient populations who might need extra support to understand the terms.
Materials and Methods
We listed 56 CTx-related terms based on the experts’ review, then 300 cancer patients and their caregivers completed a questionnaire that assessed literacy in CTx terms (LCT), functional health literacy, and empowerment. Descriptive analysis was performed to examine which CTx-related terms were most difficult for them. Logistic regression analyses were performed to identify factors associated with LCT level.
Results
Of the total 300 people, 162 (54.0%) were in the low-scoring group in LCT. Low-scoring group had a higher proportion of males, lower monthly income, and lived at the province, compared to the high scoring group. The participants tended to have difficulties in understanding terms related to blood count, risk of infection, and symptoms written in Sino-Korean. In the multivariable logistic regression, male participants (adjusted odds ratio [aOR], 2.59; 95% confidence interval [CI], 1.48 to 4.62), those with no cancer-related information-seeking (aOR, 4.32; 95% CI, 1.75 to 12.33), and those with low empowerment (aOR, 3.07; 95% CI, 1.83 to 5.23) were more likely to have a low level of LCT.
Conclusion
There were still linguistic health literacy challenges faced by cancer patients and their caregivers, specifically in understanding chemotherapy-related terms. Minimizing medical jargon and Sino-Korean terms and empowering patients to be ready for treatment are necessary.

Citations

Citations to this article as recorded by

Exploring the Perspectives of Lung Cancer Chemotherapy Patients on Self-Management: A Qualitative Interview Study Using the COM-B Model
Ruimei Jia, Nina Xie, Yue Li, Yu Zhang
Patient Preference and Adherence.2025; Volume 19: 1991. CrossRef

4,399 View
110 Download
1 Web of Science
1 Crossref

Gastrointestinal cancer

Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial: Dong Ki Lee, Choong-kun Lee, Hyo Song Kim, Sun Jin Sym, Dae Young Zang, Ki Hyang Kim, Joo Han Lim, Hae Su Kim, Kyung Hee Lee, Heon Yung Gee, Sun Young Rha, Hyunki Kim, Minkyu Jung; Cancer Res Treat. 2025;57(3):770-780. Published online November 12, 2024; DOI: https://doi.org/10.4143/crt.2024.705

Abstract PDF Supplementary Material PubReader ePub

Purpose
The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.
Materials and Methods
The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.
Results
Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.
Conclusion
The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.

Citations

Citations to this article as recorded by

The Janus Face of sFRP4 in Cancer: From Mechanistic Complexity to Therapeutic Potential
Lingqun Yu, Fei Fang, Minpu Zhang, Ye Li, Mingzhen Li, Changgang Sun, Jing Zhuang, Cun Liu
International Journal of Molecular Sciences.2026; 27(13): 5693. CrossRef

4,406 View
157 Download
1 Web of Science
1 Crossref

Lung and Thoracic cancer

Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study: Naoya Nishioka, Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Makoto Hibino, Asuka Okada, Yusuke Chihara, Hayato Kawachi, Takashi Kijima, Koichi Takayama; Cancer Res Treat. 2025;57(2):412-421. Published online October 25, 2024; DOI: https://doi.org/10.4143/crt.2024.748; Correction in: https://doi.org/

Abstract PDF Supplementary Material PubReader ePub

Purpose
Thyroid transcription factor 1 (TTF-1) expression is a useful predictor of treatment efficacy in advanced non-squamous non–small cell lung cancer (NSCLC). This study aimed to evaluate whether TTF-1 could predict the effectiveness of chemotherapy versus chemoimmunotherapy in patients with non-squamous NSCLC with programmed death ligand-1 (PD-L1) expression between 1% and 49%.
Materials and Methods
We conducted a retrospective study of patients with NSCLC who were treated with chemotherapy or chemoimmunotherapy between March 2016 and May 2023. The patients had histologically confirmed NSCLC, stage III-IV or postoperative recurrence, TTF-1 measurements, and PD-L1 expression levels between 1% and 49%. Clinical data were analyzed to evaluate the effect of TTF-1 expression on treatment efficacy.
Results
This study included 283 of 624 patients. TTF-1–positive patients showed longer progression-free survival (PFS) and overall survival (OS) (PFS: 6.4 months [95% confidence interval (CI), 5.0 to 9.4] vs. 4.1 months [95% CI, 2.7 to 6.1], p=0.03; OS: 17.9 months [95% CI, 15.2 to 28.1] vs. 9.4 months [95% CI, 6.3 to 17.0], p < 0.01) in the chemotherapy cohorts (n=93). In the chemoimmunotherapy cohort (n=190), there was no significant difference in PFS and OS between TTF-1–positive and –negative groups (PFS: 7.6 months [95% CI, 6.4 to 11.0] vs. 6.0 months [95% CI, 3.6 to 12.6], p=0.59; OS: 25.0 months [95% CI, 18.0 to 49.2] vs. 21.3 months [95% CI, 9.8 to 28.8], p=0.09).
Conclusion
In patients with NSCLC with PD-L1 expression between 1% and 49%, TTF-1 expression was a predictor of chemotherapeutic, but not chemoimmunotherapeutic, efficacy.

Citations

Citations to this article as recorded by

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors
Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti, Subba Digumarthy, Joao V. Alessi, Pooja Gogia, Grace M. Hambelton, Federica Pecci, Maisam Makarem, Malini M. Gandhi, Edoardo Garbo, Andrea De Gi
Journal of Thoracic Oncology.2026; 21(7): 103610. CrossRef
Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001)
Minehiko Inomata, Yutaro Moriyasu, Takeshi Tsuda, Yukihiro Umeda, Taro Yoneda, Yutaka Takahara, Koki Nakashima, Tomomi Ichikawa, Yuichi Tambo, Hirokazu Taniguchi, Shin Ishizawa, Kenichi Hirabayashi, Seiji Yano
Discover Oncology.2026;[Epub] CrossRef
Impact of Thyroid Transcription Factor‐1 Expression on Outcomes of Platinum‐Based Chemoimmunotherapy in Advanced or Recurrent Non‐Squamous Non‐Small Cell Lung Cancer
Ryohei Kamada, Hiroshi Yokouchi, Shohei Mizobuchi, Ken Kuwahara, Yasushi Mizukami, Hidenori Mizugaki, Noriyuki Yamada, Hajime Asahina, Hirofumi Adachi, Yoshihiro Matsuno, Satoshi Oizumi
Thoracic Cancer.2026;[Epub] CrossRef
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC
Naoya Nishioka, Daiki Murata, Koichi Azuma, Kazuhiro Ito, Takashi Nomizo, Kazuhiko Yamada, Tatsuya Imabayashi, Kentaro Iwanaga, Kenji Chibana, Takayo Ota, Yuuya Nishii, Akira Nakao, Asuka Okada, Kosuke Hamai, Takenori Sakai, Taishi Harada, Keiko Tanimura,
International Journal of Clinical Oncology.2026;[Epub] CrossRef
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis
Leonardo Brunetti, Valentina Santo, Alessandro Galletti, Alain Gelibter, Antonio Lugini, Gian Paolo Spinelli, Daniele Santini, Alessio Cortellini, Alessia Vendittelli, Giuseppina Rita Di Fazio, Fabrizio Citarella, Giulia La Cava, Emanuele Claudio Mingo, M
Cancers.2025; 17(13): 2188. CrossRef
The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinoma
Hiroyuki Yamada, Hiromu Yano, Eri Matsubara, Shukang Zhao, Yusuke Shinchi, Cheng Pan, Takamasa Koga, Kosuke Fujino, Yukio Fujiwara, Koei Ikeda, Yoshihiro Komohara, Makoto Suzuki
Human Cell.2025;[Epub] CrossRef
TTF‑1 expression is associated with survival in patients with non‑squamous non‑small cell lung cancer treated with immune checkpoint inhibitor therapy
Nozomu Murayama, Minehiko Inomata, Daisuke Furukawa, Moe Hashizume, Naoki Takata, Zenta Seto, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Kohji Takagi, Kenichi Hirabayashi
Molecular and Clinical Oncology.2025; 24(2): 1. CrossRef

8,225 View
413 Download
10 Web of Science
7 Crossref

Review Article

Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy: Chang W Song, Hyunkyung Kim, Mi-Sook Kim, Heon J Park, Sun-Ha Paek, Stephanie Terezakis, L Chinsoo Cho; Cancer Res Treat. 2025;57(1):1-10. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.255

Abstract PDF PubReader ePub

Tumor microenvironment is intrinsically hypoxic with abundant hypoxia-inducible factors-1α (HIF-1α), a primary regulator of the cellular response to hypoxia and various stresses imposed on the tumor cells. HIF-1α increases radioresistance and chemoresistance by reducing DNA damage, increasing repair of DNA damage, enhancing glycolysis that increases antioxidant capacity of tumors cells, and promoting angiogenesis. In addition, HIF-1α markedly enhances drug efflux, leading to multidrug resistance. Radiotherapy and certain chemotherapy drugs evoke profound anti-tumor immunity by inducing immunologic cell death that release tumor-associated antigens together with numerous pro-immunological factors, leading to priming of cytotoxic CD8+ T cells and enhancing the cytotoxicity of macrophages and natural killer cells. Radiotherapy and chemotherapy of tumors significantly increase HIF-1α activity in tumor cells. Unfortunately, HIF-1α effectively promotes various immune suppressive pathways including secretion of immune suppressive cytokines, activation of myeloid-derived suppressor cells, activation of regulatory T cells, inhibition of T cells priming and activity, and upregulation of immune checkpoints. Consequently, the anti-tumor immunity elevated by radiotherapy and chemotherapy is counterbalanced or masked by the potent immune suppression promoted by HIF-1α. Effective inhibition of HIF-1α may significantly increase the efficacy of radiotherapy and chemotherapy by increasing radiosensitivity and chemosensitivity of tumor cells and also by upregulating anti-tumor immunity.

Citations

Citations to this article as recorded by

Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting
Mahdieh Ameri Shah Reza, Saina Najafi, Masoumeh Kahfi, Mustafa Safari, Mohamad Mahjoor
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(2): 1711. CrossRef
Enhancing the sensitivity of radiotherapy in non-small cell lung cancer through nanotechnology-mediated reactive oxygen species generation
Xueying Bao, Zhuangzhuang Zheng, Man Li, Xuanzhong Wang, Qin Zhao, Huanhuan Wang, Ying Xin, Xin Jiang
Coordination Chemistry Reviews.2026; 549: 217234. CrossRef
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma
Yudi Liu, Ling Xiao, Xinyu Nie, Jiahua Lyu, Chengxi Tang, Linjie Li, Xue Zhang, Tao Li, Jianming Huang, Shichuan Zhang
Cancer Biology & Therapy.2026;[Epub] CrossRef
Innovative applications and future prospects of Raman spectroscopy in precision management of cancer radiotherapy and chemotherapy
Mingyu Zhang, Linlin Shao, Mingyue Ma, Ying Liu, Xin Wang, Bing Han
Applied Spectroscopy Reviews.2026; : 1. CrossRef
Historical Review of the Role of Indirect Cell Death in High-Dose Per Fraction Radiation Therapy
Chang W. Song, Lindsey Sloan, Stephanie Terezakis, Kyungmi Yang, Robert J. Griffin
Advances in Radiation Oncology.2026; 11(3): 101971. CrossRef
Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma
Emirhan Harbi, Yasemin Yozgat Byrne, Hamza Ugur Bozbey, Didem Tastekin, Oral Oncul, Soha Hosseiny, Duha Yahya, Ozcan Yildiz, Murat Erdogan, Abdul Kadir Slocum, Christopher E. Mason, Michael Aschner
Apoptosis.2026;[Epub] CrossRef
Paeoniflorigenone inhibits the progression of cholangiocarcinoma via HIF1A and enhances the chemotherapy sensitivity of cisplatin
Qing Hu, Mengqin Xiang, Feicheng Yang, Wei Guo, Mengjun Mo, Zhou Yang, Yanchun Li
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(7): 9955. CrossRef
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications
Jiayi Li, Chen Huang, Pan Tang, Ruiyan Wu, Quanyou Wu, Chenliang Zhang
Journal of Hematology & Oncology.2026;[Epub] CrossRef
Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment
Ananya H. Elati, Erika W. Davies, Mark V. Mishra, Jeffrey A. Winkles, Graeme F. Woodworth, Anthony J. Kim
Advanced Drug Delivery Reviews.2026; 232: 115811. CrossRef
From numerical amplification to functional metamorphosis: the MDSC-driven therapeutic resistance in tumor
Ruyuan Li, Anqi Zhao, Changxiang Yan, Bin Li, Zhaonian Hao
International Journal of Surgery.2026; 112(2): 4861. CrossRef
Radiotherapy as an immunomodulator in cancer: Synergy with immunotherapy and roadmap for optimization
Chenyi Zhao
Journal of Radiation Research and Applied Sciences.2026; 19(1): 102253. CrossRef
Interaction of HIF-1a with various cell death pathways in tumor immune microenvironment (TIME)
Mahsa Manafi Varkiani, Ferdos Faghihkhorasani, Mona Moosavi, Reza Habibi, Hannaneh Mirzaei, Nasrin Karimi, Sareh Etemad, Parisima Karami, Parisa Osati, Amir Reza Aref, Nasim Ebrahimi
Apoptosis.2026;[Epub] CrossRef
The tumor microenvironment as a key regulator of radiotherapy response
Xinchi Ma, Na Zhang
Frontiers in Immunology.2026;[Epub] CrossRef
Iodine-125 brachytherapy triggers immunogenic cell death and potentiates anti-PD-L1 immunotherapy in bone metastatic triple-negative breast cancer
Min Li, Zhenzhen Cui, Jiaxin Yang, Qiyu Sun, Yanbo Hu, Juan Shen, Zhihao Li, Xiaoyang Han, Yixuan Wang, Jiageng Tang, Hengsong Yu, Xiaowen Ma, Jing Wang
Frontiers in Immunology.2026;[Epub] CrossRef
The central regulator HIF-1α in digestive system pathologies: inflammation and cancer
Guoyou Gou, Min Wen, Guonian Li, Feihong Shu, Fang Wang, Youjia Liu, Rui Xie, Jingyu Xu
Frontiers in Immunology.2026;[Epub] CrossRef
Bystander effects in both hypoxic cancer and normal cells under FLASH irradiation using proton microbeams
Narongchai Autsavapromporn, Taisei Mamiya, Cuihua Liu, Aphidet Duangya, Tengku Ahbrizal Tengku Ahmad, Masakazu Oikawa, Teruaki Konishi
International Journal of Radiation Biology.2026; 102(8): 1001. CrossRef
Targeting the tumor microenvironment for sensitization of colorectal cancer to chemotherapy and radiotherapy
Jianhua Wu, Liang Zhang
Pathology - Research and Practice.2026; 283: 156480. CrossRef
From sympathetic overdrive phenotype to malignant transformation: 3PM-guided protection against health-to-disease transition and disease progression improving individual outcomes in primary and secondary care
Peter Kubatka, Andrea Kapinova, Bianka Bojkova, Vennila Joseph, Slavomir Hornak, Karol Kajo, Dietrich Büsselberg, Karel Smejkal, Vadim Goncharenko, Barbara Mrazova, Miroslava Fövényes, Rostyslav Bubnov, Walther Kuhn, Javier Conde-Aranda, Ivica Smokovski,
EPMA Journal.2026; 17(2): 205. CrossRef
A new era of natural killer cell immunotherapy in tumor treatment: latest advances and cutting-edge perspectives from basic research to clinical practice
Xin Du, Shixin Shi, Haiyan Liu
Frontiers in Immunology.2026;[Epub] CrossRef
LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia
Kexin Jin, Yang Zhao, Qiang Guo, Jingyi Lin, Hongli Zhao, Shengjin Fan, Chuiming Jia, Shuchuan Liu, Desheng Kong
iScience.2026; 29(6): 115987. CrossRef
Applications of nanoparticle drug delivery systems in breast cancer treatment: Targeting, enhanced efficacy with reduced toxicity, and overcoming drug resistance
Lei Pan, Feixia Ma, Yin Duan, Xiaoai Lv
Letters in Drug Design & Discovery.2026; 23(3): 100428. CrossRef
Boron neutron capture therapy combined with immunotherapy: insights from radiotherapy, BNCT-specific evidence, and future directions
Zeyuan Li, Haolin Cai, Xiukui Cheng, Linping Qi, Xingda Wang, Ting Yang, Can Li, Yumin Li, Cong Chen
Frontiers in Immunology.2026;[Epub] CrossRef
Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
Yan Xu, Hui Guan, Yuan Wu, Huiyu Huang, Siyuan Yu, Xiaolu Yin, Mengzhao Wang
Journal of Translational Internal Medicine.2026;[Epub] CrossRef
Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy
Georgios Maravelis, Ioannis M. Koukourakis, Pantelis Skarlos, Michael I. Koukourakis
Current Oncology.2026; 33(6): 364. CrossRef
Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer
Citing Guo, Zenan Fan, Cuiyan Guo, Yaning Yang, Helei Hou, Dantong Sun
Journal of Biomedical Science.2026;[Epub] CrossRef
Tumor-associated macrophages: potential therapeutic strategies and future prospects in radioresistance of cancer
Tianci Zhang, Ziye Zhou, Zhicheng Wang, Yanming Yang
Frontiers in Immunology.2026;[Epub] CrossRef
Remodelling the tumour microenvironment and beyond: ERO1A as a multifaceted regulator and emerging therapeutic target in cancer
Jing Mao, Kai Wang
Clinical and Translational Medicine.2026;[Epub] CrossRef
Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy
Lu Lu, Liufu Deng
Journal of Clinical Investigation.2026;[Epub] CrossRef
Down-regulation of PCK2 enhanced the radioresistance phenotype of nasopharyngeal carcinoma
Yijun He, Li Yan, Ruiqi Zhang, Rui Yang, Zhaolu Kong, Xiaosheng Wang
International Journal of Radiation Biology.2025; 101(5): 499. CrossRef
Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer
Lingyan Weng, Min Zhao, Zhongping Chen, Li Zhu
Molecular Pharmaceutics.2025; 22(4): 2142. CrossRef
Rhaponitin Reverses Cisplatin Resistance and Impairs Cancer Stemness Through HIF‐1α/MCT4/Wnt Pathway in Tongue Squamous Cell Carcinoma
Yuan Wu, Xiao‐Wen Wan, Lin Jiang, Wei Wang, Jia‐Jun Zhu, Yi‐Sen Shao
The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Stereotactic Ablative Radiotherapy for Delayed Retrobulbar Metastasis of Renal Cell Carcinoma: Therapeutic Outcomes and Practical Insights
Sang Jun Byun, Byung Hoon Kim, Seung Gyu Park, Euncheol Choi
Life.2025; 15(8): 1176. CrossRef
Low-Dose Cyclophosphamide Enhances the Tumoricidal Effects of 5-Day Spacing Stereotactic Ablative Radiotherapy by Boosting Antitumor Immunity
Hyunkyung Kim, Seok-Joo Chun, Sojung Sun, Haeun Cho, Tae-Jin Kim, Yoon-Jin Lee, Eui Kyu Chie, Kwangmo Yang, Mi-Sook Kim
Cancer Research and Treatment.2025; 57(3): 678. CrossRef
Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy
Gregg L. Semenza
Pharmacological Reviews.2025; 77(5): 100075. CrossRef
Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance
Xiaoliang Cheng, Peixing Wang, Hongqiang Lyu, Yonghyun Lee, Juyoung Yoon, Haiyan Dong
Cancer Drug Resistance.2025;[Epub] CrossRef
FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation
Valérie Gouazé-Andersson, Caroline Delmas, Yvan Nicaise, Julien Nicolau, Juan Pablo Cerapio, Elizabeth Cohen-Jonathan Moyal
Cells.2025; 14(18): 1427. CrossRef
Glycolysis-related radiosensitivity signature for predicting radiotherapy response in breast cancer
Xuan Lin, Shiyin Hu, Linyan Huang, Tianwen Xu, Jinzhi Lai
Frontiers in Immunology.2025;[Epub] CrossRef
Interrogating ABCC1 and CASP1 as key players in epigallocatechin gallate’s action against radiotherapy-resistant nasopharyngeal carcinoma
Zhang Feng, Yuhang Yang, Zhenlian Xie, Long Zuo, Zhenya Li, Congbao Wei, Jinqing Li, Yanyong Gao, Zifang Li, Dongzhi Zuo, Qianghe Liu, Guangxu Xuan, Wenqi Luo, Xuejing Tang, Shijiang Yi, Fangxian Liu, Ning Ma, Mariko Murata, Feng He
Scientific Reports.2025;[Epub] CrossRef
Concerns from bench and insights from bedside: the puzzle of Roxadustat in cancer patients with chemotherapy-induced anemia
Lin Chen, Shigen Liao, Dan Jing, Linxiu Mao, Jing Tan
Frontiers in Pharmacology.2025;[Epub] CrossRef
Role of hypoxia factors in the transcriptional mechanisms of clonal hematopoiesis in myelodysplastic syndrome
V. A. Nevzorova, A. S. Volosatov, A. V. Talko, N. S. Muzychenko, V. S. Dubov, V. M. Chertok
Pacific Medical Journal.2025; (3): 11. CrossRef

13,518 View
333 Download
41 Web of Science
40 Crossref

Original Articles

Lung and Thoracic cancer

Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial: Junghoon Shin, Sehhoon Park, Kyung Hwan Kim, Eui-Cheol Shin, Hyun Ae Jung, Jong Ho Cho, Jong-Mu Sun, Se-Hoon Lee, Yong Soo Choi, Jin Seok Ahn, Jhingook Kim, Keunchil Park, Young Mog Shim, Hong Kwan Kim, Jae Myoung Noh, Yong Chan Ahn, Hongryull Pyo, Myung-Ju Ahn; Cancer Res Treat. 2024;56(4):1084-1095. Published online April 30, 2024; DOI: https://doi.org/10.4143/crt.2024.084

Abstract PDF Supplementary Material PubReader ePub

Purpose
Optimal treatment for stage IIIA/N2 non–small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).
Materials and Methods
In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39⁺PD-1⁺CD8⁺ T cells using fold changes in the percentage of proliferating Ki-67⁺ cells from days 1 to 7 of cycle 1 (Ki-67_D7/D1).
Results
Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7/D1 among CD39⁺PD-1⁺CD8⁺ T cells than those without (p=0.036). No new safety signals were identified.
Conclusion
Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.

Citations

Citations to this article as recorded by

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
Hong Huang, Pengchen Bao, Hongyu Jin, Wenyang Li, Hui Shen, Zhen Qin, Ying Pan, Xinming Su, Delei Kong
Frontiers in Oncology.2025;[Epub] CrossRef
Advances in molecular pathology and therapy of non-small cell lung cancer
Qing Huang, Yuanxiang Li, Yingdan Huang, Jingyi Wu, Wendai Bao, Chang Xue, Xiaoyu Li, Shuang Dong, Zhiqiang Dong, Sheng Hu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
A retrospective analysis of neoadjuvant chemotherapy in pneumonectomy for locally advanced central non–small cell lung cancer
Yuchen Wang, Zhihang Dang, Pu Jiang, Zhifeng Li, Jin Yang, Kun Gao, Xiaona Chen, Jifang Yao
PeerJ.2025; 13: e20007. CrossRef

8,524 View
191 Download
3 Web of Science
3 Crossref

Gastrointestinal cancer

Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13): Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2024;56(4):1136-1145. Published online April 29, 2024; DOI: https://doi.org/10.4143/crt.2023.1324

Abstract PDF Supplementary Material PubReader ePub

Purpose
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
Materials and Methods
Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (≥ 1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks. After determining the recommended phase II dose (RP2D) in phase Ib, a phase II study was conducted to evaluate the antitumor activity.
Results
RP2D was treated with a combination of varlitinib (300 mg twice daily) and paclitaxel. Among 27 patients treated with RP2D, the median progression-free survival and overall survival (OS) were 3.3 months (95% confidence interval [CI], 1.7 to 4.9) and 7.9 months (95% CI, 5.0 to 10.8), respectively, with a median follow-up of 15.7 months. Among 16 patients with measurable disease, the objective response rate (ORR) and disease control rate were 31% and 88%, respectively. Patients with strong HER2 expression (n=8) had a higher ORR and longer OS, whereas those with strong EGFR expression (n=3) had poorer outcomes. The most common adverse events (AEs) of any grade were neutropenia (52%), diarrhea (27%), aspartate aminotransferase/alanine transaminase elevation (22%), and nausea (19%). No treatment-related deaths or unexpected AEs resulting from treatment cessation were observed in patients with RP2D.
Conclusion
A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.

Citations

Citations to this article as recorded by

Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas
Jane E. Rogers, Ashley Horak, Alicia Kroll, Jaffer A. Ajani
Expert Opinion on Emerging Drugs.2026; : 1. CrossRef
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights
Yu Aoki, Izuma Nakayama, Kohei Shitara
Current Oncology Reports.2025; 27(1): 15. CrossRef
Pharmacotherapy for previously treated gastric cancer patients: current options and future developments
Seiya Sato, Izuma Nakayama, Kohei Shitara
Expert Review of Clinical Pharmacology.2025; 18(8): 607. CrossRef
Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy
Sixiang Zheng, Ruixian Chen, Lele Zhang, Lun Tan, Lintao Li, Fangyi Long, Ting Wang
European Journal of Medicinal Chemistry.2024; 276: 116702. CrossRef

6,761 View
191 Download
4 Web of Science
4 Crossref

Head and Neck cancer

Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Yi-Feng Yu, Peng Wu, Rui Zhuo, San-Gang Wu; Cancer Res Treat. 2024;56(4):1058-1067. Published online February 19, 2024; DOI: https://doi.org/10.4143/crt.2023.1343

Abstract PDF PubReader ePub

Purpose
This study aimed to investigate the efficacy and safety of using metronomic S-1 adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
We retrospectively collected data on patients diagnosed with LANPC between January 2016 and December 2021. All patients were treated with induction chemotherapy and concurrent chemoradiotherapy with or without metronomic chemotherapy (MC). Toxicities during MC were recorded. The chi-square test, Kaplan-Meier methods, propensity score matching (PSM), and Cox proportional hazards model were used for statistical analyses.
Results
A total of 474 patients were identified, including 64 (13.5%) and 410 (83.5%) patients with or without receiving MC, respectively. Patients who received metronomic S-1 had significantly better 3-year locoregional recurrence-free survival (LRFS) (100% vs. 90.9%, p=0.038), distant metastasis-free survival (DMFS) (98.5% vs. 84.1%, p=0.002), disease-free survival (DFS) (98.4% vs. 77.5%, p < 0.001), and overall survival (OS) (98.0% vs. 87.7%, p=0.008) compared to those without metronomic S-1. The multivariate prognostic analysis revealed that metronomic S-1 was identified as an independent prognostic factor associated with better DMFS (hazard ratio [HR], 0.074; p=0.010), DFS (HR, 0.103; p=0.002) and OS (HR, 0.127; p=0.042), but not in LRFS (p=0.071). Similar results were found using PSM. Common adverse events observed in the metronomic S-1 group included leukopenia, neutropenia, increased total bilirubin, anorexia, rash/desquamation, and hyperpigmentation. All patients with adverse events were grade 1-2.
Conclusion
It is worth conducting a randomized controlled trial to assess the effect of metronomic S-1 on survival outcomes and toxicities of LANPC.

Citations

Citations to this article as recorded by

Risk Stratification in T4 or N3 Nasopharyngeal Carcinoma
Lin-Feng Guo, Lu-Chao Zhu, Yi-Feng Yu, Zhen-Zhen Lu, Qin Lin, San-Gang Wu
Cancer Research and Treatment.2026; 58(3): 728. CrossRef
Oral Metronomic Chemotherapy in Nasopharyngeal Carcinoma with Radiotherapy Interruptions: A Lesson Learned from the Lockdown Due to COVID-19
Yuan Zhou, Rui Zhou, Yi-Feng Yu, Zheng-Jie Huang, San-Gang Wu
Recent Patents on Anti-Cancer Drug Discovery.2026; 21(2): 201. CrossRef
Treatment and clinical outcomes among stage II–IVA nasopharyngeal carcinoma patients with undetectable pretreatment Epstein-Barr viral DNA
Ci-ming Sun, Zhen Xu, Cheng-hao Li, Jun-xiang Chen, Xin-yi Su, Jing-xia Song, Shuang-hong Song, Qing-qing Xu, Yan-Ling Wu
Frontiers in Medicine.2026;[Epub] CrossRef
Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
San-Gang Wu
Cancer Research and Treatment.2025; 57(1): 291. CrossRef
Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
Erkan Topkan, Efsun Somay, Nilufer Kılıc Durankus, Ugur Selek
Cancer Research and Treatment.2025; 57(1): 289. CrossRef
Two or three cycles of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma?
Lin-Feng Guo, Yi-Feng Yu, Zhen-Zhen Lu, Qin Lin, San-Gang Wu
BMC Cancer.2025;[Epub] CrossRef
Comment on “Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles”
Erkan Topkan, Efsun Somay, Duriye Ozturk, Ugur Selek
Clinical and Translational Radiation Oncology.2025; 54: 101025. CrossRef
Genetic algorithm-optimized neural network outperforms TNM staging in predicting rapidly progressive nasopharyngeal carcinoma: Reassessing adjuvant chemotherapy benefit via propensity score matching
Li-ting Ling, Wang-jian Li, Yue Yao, Kai-qing Tan, Bo-lin Zhu, Li-Qing Zhou, Song Qu, Ling Li, Ying Guan, Xiao-dong Zhu, Ling-hui Pan, Zhong-guo Liang
European Journal of Cancer.2025; 230: 115787. CrossRef
Metronomic chemotherapy in locoregionally advanced nasopharyngeal carcinoma with residual EBV-DNA after induction chemotherapy
Lin-Feng Guo, Liu-Yun Gong, Qin Lin, San-Gang Wu
Infectious Agents and Cancer.2025;[Epub] CrossRef
Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study
Shuhui Dong, Weixin Bei, Lanfeng Lin, Yaofei Jiang, Nian Lu, Guoying Liu, Yanqun Xiang, Weixiong Xia
Oral Oncology.2024; 156: 106908. CrossRef

6,637 View
151 Download
9 Web of Science
10 Crossref

Genitourinary cancer

Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study: Junho Lee, Sung Hee Lim, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park; Cancer Res Treat. 2024;56(3):871-876. Published online January 16, 2024; DOI: https://doi.org/10.4143/crt.2023.1226

Abstract PDF PubReader ePub

Purpose
The aim of this retrospective study was to evaluate the efficacy of adjuvant cisplatin-based chemotherapy in patients with locally advanced upper tract urothelial carcinoma (UTUC), administered following radical nephroureterectomy.
Materials and Methods
Patients with UTUC, arising from renal pelvis or ureter, staged pT3/T4 or N+ were treated with adjuvant chemotherapy following surgery. The chemotherapy consisted of gemcitabine 1,000 mg/m² on days 1 and 8, cisplatin 70 mg/m² on day 1. Treatment was repeated every 3 weeks for up to 4 cycles. Endpoints included disease-free survival (DFS), metastasis-free survival (MFS), and safety.
Results
Among 89 eligible patients, 85 (95.5%) completed at least 3 cycles of adjuvant chemotherapy. Chemotherapy was well tolerated, the main toxicities being mild-to-moderate gastrointestinal toxic effects and pruritus. With a median follow-up of 37 months, median DFS was 30 months (95% confidence interval, 22 to 39), and the median MFS was not reached. The 3-year DFS and MFS were 44% and 56%, respectively. Multivariate analyses revealed that the main factor associated with DFS and MFS was the lymph node involvement, whereas age, T category, grade, or the primary site of UTUC were not significantly associated with DFS or MFS.
Conclusion
Adjuvant cisplatin-based chemotherapy after radical surgery of pT3/T4 or N+ UTUC was feasible and may demonstrate benefits in DFS and MFS. Whether novel agents added to the chemotherapy regimen, as a concurrent combination or maintenance, impacts on survival or reduces the development of metastases remains to be studied.

Citations

Citations to this article as recorded by

Scientific advances in drug development and clinical trials for urothelial carcinoma: Highlights from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium
Ruicheng Wu, Dengxiong Li, Dechao Feng
Asian Journal of Urology.2026; 13(2): 246. CrossRef
Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study
Cheng Wang, Shuaipeng He, Dan Li, Biao Zhang, Yu Dai, Can Li, Xuan Li, Le Kang, Shujun Yang, Su Zhang, Ning Fan, Hong Chang, Gongjin Wu, Zhongjin Yue, Junhai Ma, Panfeng Shang
Frontiers in Immunology.2026;[Epub] CrossRef
Perioperative and oncological outcomes of single position retroperitoneoscopic radical nephroureterectomy for upper urinary tract urothelial carcinoma
Jiaqiang Chen, Luxin Zhang, Zhihong Dai, Cheng Chang, Heyao Tong, Hepeng Cui, Zhuwei Song, Bo Fan, Zhiyu Liu, Liang Wang
Scientific Reports.2025;[Epub] CrossRef
Cisplatin/gemcitabine

Reactions Weekly.2024; 2027(1): 127. CrossRef

8,734 View
159 Download
3 Web of Science
4 Crossref

Gastrointestinal cancer

Combined High-Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-institutional Cohort Study: Jung Ho Im, Jeong Il Yu, Tae Hyun Kim, Tae Gyu Kim, Jun Won Kim, Jinsil Seong; Cancer Res Treat. 2024;56(3):838-846. Published online January 2, 2024; DOI: https://doi.org/10.4143/crt.2023.886

Abstract PDF Supplementary Material PubReader ePub

Purpose
The locally advanced unresectable intrahepatic cholangiocarcinoma (ICC) has detrimental oncological outcomes. In this study, we aimed to investigate the efficacy of radiotherapy in patients with locally advanced unresectable ICC.
Materials and Methods
Between 2001 and 2021, 116 patients were identified through medical record who underwent radiotherapy for locally advanced unresectable ICC. The resectability of ICC is determined by the multidisciplinary team at each institution. Overall survival (OS) were analyzed using the Kaplan-Meier method, and prognostic factors were analyzed using the Cox proportional hazards model.
Results
The median equivalent radiotherapy dose in 2 Gy fractions (EQD2) was 52 Gy (range, 30 to 110 Gy). Forty-seven patients (40.5%) received sequential gemcitabine-cisplatin based chemotherapy (GEM-CIS CTx). Multivariate analysis identified two risk factors, EQD2 of ≥ 60 Gy and application of sequential GEM-CIS CTx for OS. Patients were grouped by these two risk factors: group 1, EQD2 ≥ 60 Gy with sequential GEM-CIS CTx (n=25); group 2, EQD2 < 60 Gy with sequential GEM-CIS CTx or fluoropyrimidine-based concurrent chemoradiotherapy (n=70); and group 3, radiotherapy alone (n=21). Curative resection was more frequently undergone in group 1 than in groups 2 or 3 (28% vs. 8.6% vs. 0%, respectively). Consequently, OS was significantly better in group 1 than in groups 2 and 3 (p < 0.05).
Conclusion
Combined high-dose radiotherapy with sequential GEM-CIS CTx improved oncologic outcomes in patients with locally advanced unresectable ICC. Further prospective studies are required to validate these findings.

Citations

Citations to this article as recorded by

Immunotherapy checkpoint inhibitor-combination therapy versus chemotherapy alone among Chinese population in cholangiocarcinoma treatment: a systematic review and meta-analysis
Li Shi, Wei Du, Juan Miao, Xi-Yuan Peng, Wei Li, Attiq Ur-Rehman, Meng-Wei Ge, Lu-Ting Shen, Rui Feng, Kang Zhong, Si-Qi Gao, Hong-Lin Chen
European Journal of Clinical Pharmacology.2026;[Epub] CrossRef
The role of radiotherapy in the management of combined hepatocellular-cholangiocarcinoma: current evidence and future perspectives
Seo Hee Choi, Woong Sub Koom, Ik Jae Lee
Journal of Liver Cancer.2026; 26(1): 55. CrossRef
Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges
Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang
World Journal of Gastroenterology.2025;[Epub] CrossRef
Optimizing radiotherapy in unresectable or metastatic intrahepatic cholangiocarcinoma: systematic review and meta-analysis of the literature
Ik Jae Lee, Ji-In Bang, Seo Hee Choi, Jung Ho Im
Radiation Oncology.2025;[Epub] CrossRef

7,319 View
158 Download
5 Web of Science
4 Crossref

Pediatric cancer

Long-term Outcomes of Protocol-Based Treatment for Newly Diagnosed Medulloblastoma: Won Kee Ahn, Seung Min Hahn, Hong In Yoon, Jeongshim Lee, Eun Kyung Park, Kyu Won Shim, Dong Seok Kim, Chang-Ok Suh, Se Hoon Kim, Chuhl Joo Lyu, Jung Woo Han; Cancer Res Treat. 2024;56(2):652-664. Published online November 30, 2023; DOI: https://doi.org/10.4143/crt.2023.865

Abstract PDF Supplementary Material PubReader ePub

Purpose
The Korean Society of Pediatric Neuro-Oncology (KSPNO) conducted treatment strategies for children with medulloblastoma (MB) by using alkylating agents for maintenance chemotherapy or tandem high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) according to the risk stratification. The purpose of the study was to assess treatment outcomes and complications based on risk-adapted treatment and HDC.
Materials and Methods
Fifty-nine patients diagnosed with MB were enrolled in this study. Patients in the standard-risk (SR) group received radiotherapy (RT) after surgery and chemotherapy using the KSPNO M051 regimen. Patients in the high-risk (HR) group received two and four chemotherapy cycles according to the KSPNO S081 protocol before and after reduced RT for age following surgery and two cycles of tandem HDC with ASCR consolidation treatment.
Results
In the SR group, 24 patients showed 5-year event-free survival (EFS) and overall survival (OS) estimates of 86.7% (95% confidence interval [CI], 73.6 to 100) and 95.8% (95% CI, 88.2 to 100), respectively. In the HR group, more infectious complications and mortality occurred during the second HDC than during the first. In the HR group, the 5-year EFS and OS estimates were 65.5% (95% CI, 51.4 to 83.4) and 72.3% (95% CI, 58.4 to 89.6), respectively.
Conclusion
High intensity of alkylating agents for SR resulted in similar outcomes but with a high incidence of hematologic toxicity. Tandem HDC with ASCR for HR induced favorable EFS and OS estimates compared to those reported previously. However, infectious complications and treatment-related mortalities suggest that a reduced chemotherapy dose is necessary, especially for the second HDC.

Citations

Citations to this article as recorded by

Neurocognitive outcomes following postoperative paediatric cerebellar mutism syndrome: A systematic review
Bethany M. Horne, Annisha A. Attanayake, Kristian Aquilina, Tara Murphy, Charlotte P. Malcolm
Developmental Medicine & Child Neurology.2026; 68(1): 29. CrossRef
Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study
Gerdi Tuli, Jessica Munarin, Paola Ragazzi, Eleonora Biasin, Francesco Felicetti, Anna Mussano, Stefano Gabriele Vallero, Daniele Bertin, Paola Peretta, Giovanni Morana, Franca Fagioli, Luisa De Sanctis
Journal of Clinical Medicine.2026; 15(9): 3472. CrossRef
Ferroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq
Christophe Desterke, Yuanji Fu, Jenny Bonifacio-Mundaca, Claudia Monge, Pascal Pineau, Jorge Mata-Garrido, Raquel Francés
Antioxidants.2025; 14(1): 96. CrossRef

7,361 View
188 Download
3 Web of Science
3 Crossref

Tandem High-Dose Chemotherapy Increases the Risk of Secondary Malignant Neoplasm in Pediatric Solid Tumors: Hana Lim, Minji Im, Eun Seop Seo, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Sung Yoon Cho, Jong-Won Kim, Do Hoon Lim, Ki Woong Sung, Ji Won Lee; Cancer Res Treat. 2024;56(2):642-651. Published online November 24, 2023; DOI: https://doi.org/10.4143/crt.2023.999

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the incidence and risk factors for secondary malignant neoplasms (SMN) in pediatric solid tumors, focusing on the effects of tandem high-dose chemotherapy (HDCT).
Materials and Methods
Patients (aged < 19 years) diagnosed with or treated for pediatric solid tumors between 1994 and 2014 were retrospectively analyzed. The cumulative incidence of SMN was estimated using competing risk methods by considering death as a competing risk.
Results
A total of 1,435 patients (413 with brain tumors and 1,022 with extracranial solid tumors) were enrolled. Seventy-one patients developed 74 SMNs, with a 10-year and 20-year cumulative incidence of 2.680±0.002% and 10.193±0.024%, respectively. The types of SMN included carcinoma in 28 (37.8%), sarcoma in 24 (32.4%), and hematologic malignancy in 15 (20.3%) cases. Osteosarcoma and thyroid carcinoma were the most frequently diagnosed tumors. Multivariate analysis showed that radiotherapy (RT) > 2, 340 cGy, and tandem HDCT were significant risk factors for SMN development. The SMN types varied according to the primary tumor type; carcinoma was the most frequent SMN in brain tumors and neuroblastoma, whereas hematologic malignancy and sarcomas developed more frequently in patients with sarcoma and retinoblastoma, respectively.
Conclusion
The cumulative incidence of SMN in pediatric patients with solid tumors was considerably high, especially in patients who underwent tandem HDCT or in those who received RT > 2,340 cGy. Therefore, the treatment intensity should be optimized based on individual risk assessment and the long-term follow-up of pediatric cancer survivors.

Citations

Citations to this article as recorded by

Contribution of Germline Predisposition to Pediatric Thyroid Cancer
Claudia Harrison, Alise K. Blake, Yin Su, Li Tang, Ninad Oak, Lynn Harrison, Regina Nuccio, Rose B. McGee, Lilyanne Grieve, Arti S. Pandey, Leslie M. Taylor, Manish Kubal, Stacy J. Hines-Dowell, Anthony Sheyn, Zachary Abramson, Melissa Perrino, Sara Feder
Clinical Cancer Research.2025; 31(17): 3787. CrossRef
Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models
Hanqiang Jin, Ruoyu Chen, Yonggang Wang, Jin Huang, Xue-ping Cao, Hafiz Khuram Raza, Xian-long Fang, Kang-jian Zhang, Ning Li, Shumin Zhou, Qingcheng Yang
Scientific Reports.2025;[Epub] CrossRef
Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma
Katja Seipel, Nuria Z. Veglio, Henning Nilius, Barbara Jeker, Ulrike Bacher, Thomas Pabst
Current Issues in Molecular Biology.2024; 46(8): 8197. CrossRef

6,372 View
162 Download
3 Web of Science
3 Crossref

General

Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study: Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Sang-We Kim, Dae Ho Lee, Jae Cheol Lee, Chang-Min Choi, Shinkyo Yoon, Su-Jin Koh, Young Joo Min, Yongchel Ahn, Hwa Jung Kim, Jin Ho Baek, Sook Ryun Park, Jee Hyun Kim; Cancer Res Treat. 2024;56(2):404-413. Published online November 7, 2023; DOI: https://doi.org/10.4143/crt.2023.784

Abstract PDF Supplementary Material PubReader ePub

Purpose
The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex.
Materials and Methods
This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea.
Results
A total of 1,170 patients with colorectal, gastric, or non–small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade ≥ 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits.
Conclusion
Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions.

Citations

Citations to this article as recorded by

Survival benefit of adjuvant chemotherapy for perihilar cholangiocarcinoma: Impact of log odds of metastatic lymph node count
Jun Kawashima, Miho Akabane, Odysseas P. Chatzipanagiotou, Diamantis I. Tsilimigras, Zayed Rashid, Mujtaba Khalil, Abdullah Altaf, Yutaka Endo, Kota Sahara, Federico Aucejo, Hugo P. Marques, Beatriz Chumbinho, Tom Hugh, Shishir K. Maithel, Bas Groot Koerk
Surgery.2026; 191: 109913. CrossRef
Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events
Rakchha Chhetri, Natansh D Modi, Bradley D Menz, Erik Cornelisse, David Postma, Nicole M Kuderer, Gary H Lyman, Sandra M Swain, Lee X Li, Ahmad Y Abuhelwa, Ross A McKinnon, Sina Vatandoust, Ganessan Kichenadasse, Andrew Rowland, Michael J Sorich, Ashley M
JNCI: Journal of the National Cancer Institute.2026; 118(7): 1219. CrossRef
Chemotherapy-Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors, and Management Patterns
Natalie Khamashta, Ahmad Dalal, Mo’men Alashwas, Musab Hamdan, Fuad Al-Rimawi, Yousef Sahoury
Cancer Research Communications.2026; 6(7): 1714. CrossRef
Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study
Linlin Guo, Qian Zhang, Mengmei Zhang, Xiaohang Zhong, Yadong Song, Yongcheng Fu, Zhaorui Wang, Haozhe Zhang, Youfu He, Chao Li
Technology in Cancer Research & Treatment.2026;[Epub] CrossRef
Toxicidad del esquema FOLFOX-6, asociado o no a bolo de 5-fluorouracilo, en cáncer colorrectal metastásico
María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
Farmacia Hospitalaria.2025; 49(3): 154. CrossRef
Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
Elizabeth J. Cathcart‐Rake, Alexandre Chan, Alvaro Menendez, Denise Markstrom, Carla Schnitzlein, Yee Won Chong, Don S. Dizon
CA: A Cancer Journal for Clinicians.2025; 75(1): 68. CrossRef
Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats
Chiara Di Marino, Álvaro Llorente-Berzal, Alba M. Diego, Ariadni Bella, Laura Boullon, Esther Berrocoso, Michelle Roche, David P. Finn
Frontiers in Pharmacology.2025;[Epub] CrossRef
[Translated article] Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer
María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
Farmacia Hospitalaria.2025; 49(3): T154. CrossRef
The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma
Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, Mujtaba Khalil, Miho Akabane, François Cauchy, Feng Shen, Shishir Maithel, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, Luca Aldrighetti, George Poultsides, Andrea Ru
Annals of Surgical Oncology.2025; 32(6): 4341. CrossRef
Neurobehavioral manifestations in female rats after intermittent exposure to an anticancer agent, paclitaxel
Deepika Pathak, K.P. Singh
Behavioural Pharmacology.2025; 36(5): 276. CrossRef
Gender‐Affirming Hormone Therapy: Pharmacokinetic Considerations for Oncology in Transgender Patients
Anna Carollo, Lavinia Piazza, Alessio Provenzani
Clinical and Translational Science.2025;[Epub] CrossRef

6,879 View
183 Download
10 Web of Science
11 Crossref

Gastrointestinal cancer

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer: Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-kun Lee, Hong Jae Chon; Cancer Res Treat. 2023;55(4):1291-1302. Published online May 3, 2023; DOI: https://doi.org/10.4143/crt.2022.1450

Abstract PDF Supplementary Material PubReader ePub

Purpose
There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC.
Materials and Methods
Genomic analysis of advanced BTC multi-institutional cohorts was performed using targeted panel sequencing. Genomic alterations were analyzed integrating patients’ clinicopathologic data, including clinical outcomes of Gem/Cis-based therapy. Significance of genetic alterations was validated using clinical next-generation sequencing (NGS) cohorts from public repositories and drug sensitivity data from cancer cell lines.
Results
193 BTC patients from three cancer centers were analyzed. Most frequent genomic alterations were TP53 (55.5%), KRAS (22.8%), ARID1A (10.4%) alterations, and ERBB2 amplification (9.8%). Among 177 patients with BTC receiving Gem/Cis-based chemotherapy, ARID1A alteration was the only independent predictive molecular marker of primary resistance showing disease progression for 1st-line chemotherapy in the multivariate regression model (odds ratio, 3.12; p=0.046). In addition, ARID1A alteration was significantly correlated with inferior progression-free survival on Gem/Cis-based chemotherapy in the overall patient population (p=0.033) and in patients with extrahepatic cholangiocarcinoma (CCA) (p=0.041). External validation using public repository NGS revealed that ARID1A mutation was a significant predictor for poor survival in BTC patients. Investigation of multi-OMICs drug sensitivity data from cancer cell lines revealed that cisplatin-resistance was exclusively observed in ARID1A mutant bile duct cancer cells.
Conclusion
Integrative analysis with genomic alterations and clinical outcomes of the first-line Gem/Cis-based chemotherapy in advanced BTC revealed that patients with ARID1Aalterations showed a significant worse clinical outcome, especially in extrahepatic CCA. Well-designed prospective studies are mandatory to validate the predictive role of ARID1Amutation.

Citations

Citations to this article as recorded by

Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine–cisplatin: A prospective observational cohort study
Seonjeong Woo, Beodeul Kang, Sung Hwan Lee, Jung Sun Kim, Haeyoun Kang, Seok Jeong Yang, Chansik An, Gwangil Kim, Gae Hoon Jo, Chang-Il Kwon, Min Je Sung, Suk Pyo Shin, Sanghoon Jung, Sohyun Hwang, Chan Kim, Hong Jae Chon
Hepatology.2026; 84(3): 726. CrossRef
HER2 Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-institutional Analysis
Sunyoung S. Lee, Dong Hyun Seo, Taek Chung, Daniel Fox, Jaime Ivan Haro-Silerio, Chang Gon Kim, Jeong Eun Yoo, Deepak Bhamidipati, Sang Hun Lee, Funda Meric-Bernstam, Shubham Pant, Hye Jin Choi, Milind Javle, Choong-kun Lee
Clinical Cancer Research.2026; 32(9): 1745. CrossRef
Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction
S. Conroy, H. Gagg, LA Quayle, JA Adams, ST Williams, T. Helleday, SA Hussain, J. Griffin, R. Allen, JK Rantala, SJ Danson, JWF Catto, G. Wells
Communications Medicine.2026;[Epub] CrossRef
Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon
Journal of Hepatology.2025; 82(4): 649. CrossRef
The role of ARID1A in malignant neoplasms of the female reproductive system: a modern view on diagnostic and therapeutic opportunities
A. I. Marzaganova, I. R. Martirosyan, A. S. Korchemkina, E. G. Avanesyan, D. A. Korkmazova, O. B. Grakhnova, V. V. Akimina, A. P. Dzhamalutdinova, D. A. Bolloev, A. M. Dugulbgova, Z. G. Bakhmudova, A. T. Salikhova, P. A. Dzigora
Obstetrics, Gynecology and Reproduction.2025; 19(2): 282. CrossRef
Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization
Rattanaporn Jaidee, Apinya Jusakul, Piman Pocasap, Veerapol Kukongviriyapan, Laddawan Senggunprai, Auemduan Prawan, Watcharin Loilome, Attapol Titapun, Apiwat Jareanrat, Vasin Thanasukarn, Natcha Khuntikeo, Nisana Namwat, Yaovalux Chamgramol, Malinee Than
Scientific Reports.2025;[Epub] CrossRef
Epidemiology and genomic features of biliary tract cancer and its unique features in Korea
Seonjeong Woo, Youngun Kim, Sohyun Hwang, Hong Jae Chon
Journal of Liver Cancer.2025; 25(1): 41. CrossRef
Prognostic Role of MTAP Loss in Cholangiocarcinoma
James Lyon, Soravis Osataphan, Vaibhav Birda, Brian Russell, Charly Edmiston, Rodrigo Paredes, Ahmed Rattani, Mary Linton Peters
JCO Precision Oncology.2025;[Epub] CrossRef
Predicting cisplatin response in cholangiocarcinoma patients using chromosome pattern and related gene expression
Sutheemon Techa-ay, Sasithorn Watcharadetwittaya, Raksawan Deenonpoe, Kitti Intuyod, Waleeporn Kaewlert, Anchalee Techasen, Watcharin Loilome, Poramate Klanrit, Manida Suksawat, Kwanjira Chaleekan, Sirinya Sitthirak, Malinee Thanee
Scientific Reports.2025;[Epub] CrossRef
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer
Ozlem Yedier-Bayram, Ahmet Cingöz, Ebru Yilmaz, Ali Cenk Aksu, Beril Esin, Nareg Degirmenci, Ayse Derya Cavga, Beyza Dedeoğlu, Buse Cevatemre, Hamzah Syed, Martin Philpott, Adam P. Cribbs, Udo Oppermann, Nathan A. Lack, Ceyda Acilan, Tamer T. Onder, Tugba
Experimental & Molecular Medicine.2025; 57(6): 1294. CrossRef
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplat
Hongsik Kim, Chiyoon Oum, Soo Ick Cho, Wonkyung Jung, Hong Jae Chon, Myung Ah Lee, Hyeon-Su Im, Min Hwan Kim, Taekjin Nam, Chan-Young Ock, Hye Jin Choi, Choong-kun Lee
JCO Precision Oncology.2025;[Epub] CrossRef
Evolving precision: Updates in targeted therapy for cholangiocarcinoma
Giulia Tesini, Halima Ibrahim, Lorenza Rimassa, Chiara Braconi
Hepatology.2025;[Epub] CrossRef
ARID1A in Gynecologic Precancers and Cancers
Jaida E. Morgan, Nishah Jaferi, Zainab Shonibare, Gloria S. Huang
Reproductive Sciences.2024; 31(8): 2150. CrossRef
Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report
Koji Kameyama, Kosuke Mizutani, Tetsuya Yamada, Seiji Sugiyama, Shingo Kamei, Shigeaki Yokoi, Kengo Matsunaga, Koseki Hirade, Yasutaka Kato, Hiroshi Nishihara, Satoshi Ishihara, Takashi Deguchi
Molecular and Clinical Oncology.2024;[Epub] CrossRef
A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma
Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan
Clinical and Translational Oncology.2024; 27(3): 1166. CrossRef
Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors
Jiumei Zhao, Jing Zhu, Yu Tang, Kepu Zheng, Ziwei Li
Frontiers in Oncology.2024;[Epub] CrossRef

8,765 View
372 Download
15 Web of Science
16 Crossref

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma: Seong Yong Park, Hong Kwan Kim, Yeong Jeong Jeon, Junghee Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jae Il Zo; Cancer Res Treat. 2023;55(4):1231-1239. Published online April 24, 2023; DOI: https://doi.org/10.4143/crt.2022.1417

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the efficacy of adjuvant chemotherapy after neoadjuvant chemoradiotherapy (CCRTx) followed by surgery in patients with esophageal squamous cell carcinoma (ESCC).
Materials and Methods
We retrospectively analyzed the data from 382 patients who received neoadjuvant CCRTx and esophagectomy for ESCC between 2003 and 2018.
Results
This study included 357 (93.4%) men, and the years median patient age was 63 (range, 40 to 84 years). Overall, 69 patients (18.1%) received adjuvant chemotherapy, whereas 313 patients (81.9%) did not. The median follow-up period was 28.07 months (interquartile range, 15.50 to 62.59). The 5-year overall survival (OS) and disease-free survival were 47.1% and 42.6%, respectively. Adjuvant chemotherapy did not improve OS in all patients, but subgroup analysis revealed that adjuvant chemotherapy improved the 5-year OS in patients with ypT+N+ (24.8% vs. 29.9%, p=0.048), whereas the survival benefit of adjuvant chemotherapy was not observed in patients with ypT0N0, ypT+N0, or ypT0N+. Multivariable analysis revealed that ypStage and adjuvant chemotherapy (hazard ratio, 0.601; p=0.046) were associated with OS in patients with ypT+N+. Freedom from distant metastasis was marginally different according to the adjuvant chemotherapy (48.3% vs. 41.3%, p=0.141).
Conclusion
Adjuvant chemotherapy after neoadjuvant therapy followed by surgery reduces the distant metastasis in ypT+N+ ESCC patients, thereby improving the OS. The consideration could be given to administration of adjuvant chemotherapy to ypT+N+ ESCC patients with tolerable conditions.

Citations

Citations to this article as recorded by

Impact of adjuvant therapy on survival in esophageal cancer patients after neoadjuvant therapy investigated by a population based cohort study
Jia-Lei Huang, Zi-Xin Lin, Ke-Yi Zeng, Zheng Lu, Xuan-Ping Lin, He-Rui Wang, Yong-Wei Xie, Jing-Rong Yang
Scientific Reports.2026;[Epub] CrossRef
Postoperative Adjuvant Therapy Benefits Non‐pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real‐World Study
Defeng Liu, Ao Liu, Longxiang Guo, Yi Li, Yuanlin Li, Yuxiang Chi, Haiqun Lin, Jinming Yu, Minghuan Li
Thoracic Cancer.2025;[Epub] CrossRef
Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation
Yoo Kyung Choi, Seok Hyun Son, Hong Seok Jang, In-Ho Kim, Sea-Won Lee, Soo-Yoon Sung, Satyajeet Rath
PLOS One.2025; 20(11): e0336794. CrossRef
Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study
Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Frontiers in Immunology.2024;[Epub] CrossRef
Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer
Ruiya Ma, Yoshinaga Okugawa, Tadanobu Shimura, Shinji Yamashita, Yuhki Sato, Chengzeng Yin, Ryo Uratani, Takahito Kitajima, Hiroki Imaoka, Mikio Kawamura, Yuhki Morimoto, Yoshiki Okita, Shigeyuki Yoshiyama, Masaki Ohi, Yuji Toiyama
Surgical Oncology.2024; 53: 102044. CrossRef
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen
Frontiers in Immunology.2024;[Epub] CrossRef

6,712 View
175 Download
9 Web of Science
6 Crossref

General

A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy: Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim; Cancer Res Treat. 2023;55(4):1096-1103. Published online April 7, 2023; DOI: https://doi.org/10.4143/crt.2022.1565

Abstract PDF Supplementary Material PubReader ePub

Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by

Ethanol intoxication in paediatric patients receiving intravenous etoposide as conditioning regimen for allogenic hematopoietic stem cell transplant
Pauline Claraz, Marie de Tersant, Valentine Feyants, Julie Roupret-Serzec, Thomas Storme, Jean-Hugues Dalle
Journal of Oncology Pharmacy Practice.2026; 32(6): 1032. CrossRef
Impact of spacer chain length on self-assembly of paclitaxel-biotin conjugates
Dmitry V. Beigulenko, Inna V. Zhezher, Ekaterina S. Kazakova, Aleksander S. Peregudov, Tatyana S. Kovshova, Aleksey A. Nikitin, Konstantin A. Kochetkov
Journal of Pharmaceutical Sciences.2026; 115(6): 104263. CrossRef
Self-assembled leuprolide-oleic acid nanoparticles encapsulating docetaxel for synergistic drug delivery
Jeongro Lee, Hy Dinh Nguyen, Sura Saad Abdullah, Raimar Löbenberg, Beom-Jin Lee
International Journal of Pharmaceutics.2025; 685: 126235. CrossRef
Evaluation of self-assembling properties of paclitaxel-biotin conjugates
Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
Nano-Structures & Nano-Objects.2024; 40: 101375. CrossRef

6,738 View
232 Download
4 Web of Science
4 Crossref

Gastrointestinal cancer

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX: So Heun Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-pyo Kim, Sora Kang, Jae Ho Jeong, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Yejong Park, Bong Jun Kwak, Heung-Moon Chang, Baek-Yeol Ryoo, Song Cheol Kim; Cancer Res Treat. 2023;55(3):956-968. Published online February 27, 2023; DOI: https://doi.org/10.4143/crt.2022.409

Abstract PDF Supplementary Material PubReader ePub

Purpose
The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population.
Materials and Methods
This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. The association of adjuvant chemotherapy with disease-free survival (DFS) and overall survival (OS) was evaluated in overall patients and in the propensity score matched (PSM) cohort. Subgroup analysis was conducted according to the pathology-proven lymph node status.
Results
Adjuvant chemotherapy was administered to 149 patients (68.3%). In the overall cohort, the adjuvant chemotherapy group had significantly improved DFS and OS compared to the observation group (DFS: median, 13.8 months [95% confidence interval (CI), 11.0 to 19.1] vs. 8.2 months [95% CI, 6.5 to 12.0]; p < 0.001; and OS: median, 38.0 months [95% CI, 32.2 to not assessable] vs. 25.7 months [95% CI, 18.3 to not assessable]; p=0.005). In the PSM cohort of 57 matched pairs of patients, DFS and OS were better in the adjuvant chemotherapy group than in the observation group (p < 0.001 and p=0.038, respectively). In the multivariate analysis, adjuvant chemotherapy was a significant favorable prognostic factor (vs. observation; DFS: hazard ratio [HR], 0.51 [95% CI, 0.36 to 0.71; p < 0.001]; OS: HR, 0.45 [95% CI, 0.29 to 0.71; p < 0.001]).
Conclusion
Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.

Citations

Citations to this article as recorded by

Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis
Michael C. Frey, Victor Lopez-Lopez, Alessia Benz, Sarvar Abdurakhmonov, Haleh Amirian, Jashodeep Datta, So Heun Lee, Changhoon Yoo, Ning Pu, Chunmeng Zhang, Bradley N. Reames, Ralph Fritsch, Henrik Petrowsky, José Oberholzer, Dilmurodjon Eshmuminov
Annals of Surgical Oncology.2026;[Epub] CrossRef
Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma
Seif Elmankabadi, Amir G. Ashraf, Laleh Foroutani, Thomas M. Li, Carlos Corvera, Kenzo Hirose, Kimberly Kirkwood, Eric Nakakura, Adnan Alseidi, Mohamed Adam
European Journal of Surgical Oncology.2026; 52(8): 111955. CrossRef
Chemotherapy Completion as a Quality Metric in Resected Pancreatic Ductal Adenocarcinoma
Robert C. G. Martin, Ryan A. Cantrell, Jeremy T. Gaskins
Cancers.2026; 18(12): 1912. CrossRef
Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis
Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink
JNCI: Journal of the National Cancer Institute.2025; 117(5): 840. CrossRef
Chemotherapy hypersensitivity: Current insights and novel desensitization strategies
Gordon K.H. Chu, Andy K.C. Kan, James K.Y. Hooi, Hye-Ryun Kang, Philip H. Li
Journal of Allergy and Hypersensitivity Diseases.2025; 6: 100042. CrossRef
Radiotherapy of pancreatic cancer patients. Past and present: a review
M. A. Ilin, S. D. Trotsenko, M. V. Podolskaya
Diagnostic radiology and radiotherapy.2025; 16(2): 20. CrossRef
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
Julia Groszewska, Michał Romaniuk, Ewa Małecka-Wojciesko
International Journal of Translational Medicine.2025; 5(4): 55. CrossRef
The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database
Hao Hu, Yang Xu, Qiang Zhang, Yuan Gao, Zhenyu Wu
Expert Review of Anticancer Therapy.2024; 24(6): 467. CrossRef
Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how
Nebojsa Manojlovic, Goran Savic, Stevan Manojlovic
World Journal of Gastrointestinal Surgery.2024; 16(5): 1223. CrossRef
Case Study on Analysing the Early Disease Detection of Pancreatic Ductal Adenocarcinoma in Korean Association for Clinical Oncology
Sijithra Ponnarassery Chandran, N. Santhi
American Journal of Clinical Oncology.2024; 47(10): 475. CrossRef
Evaluating the benefits of adjuvant chemotherapy in patients with pancreatic cancer undergoing radical pancreatectomy after neoadjuvant therapy—a systematic review and meta-analysis
Jiahao Wu, Yike Zhang, Haodong Wang, Wenyi Guo, Chengqing Li, Yichen Yu, Han Liu, Feng Li, Lei Wang, Jianwei Xu
Frontiers in Oncology.2024;[Epub] CrossRef

10,256 View
189 Download
9 Web of Science
11 Crossref

General

Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study: Yae Jee Baek, Youn-Jung Lee, So Ra Park, Kyoo Hyun Kim, Seung-Hoon Beom, Choong-kun Lee, Sang Joon Shin, Sun Young Rha, Sinyoung Kim, Kyoung Hwa Lee, Jung Ho Kim, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, Minkyu Jung, Jin Young Ahn; Cancer Res Treat. 2023;55(3):746-757. Published online February 9, 2023; DOI: https://doi.org/10.4143/crt.2022.1541

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to assess the humoral response to and reactogenicity of coronavirus disease 2019 (COVID-19) vaccination according to the vaccine type and to analyze factors associated with immunogenicity in actively treated solid cancer patients (CPs).
Materials and Methods
Prospective cohorts of CPs, undergoing anticancer treatment, and healthcare workers (HCWs) were established. The participants had no history of previous COVID-19 and received either mRNA-based or adenovirus vector–based (AdV) vaccines as the primary series. Blood samples were collected before the first vaccination and after 2 weeks for each dose vaccination. Spike-specific binding antibodies (bAbs) in all participants and neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type, Delta, and Omicron variants in CPs were analyzed and presented as the geometric mean titer.
Results
Age-matched 20 HCWs and 118 CPs were included in the analysis. The bAb seroconversion rate and antibody concentrations after the first vaccination were significantly lower in CPs than in HCWs. After the third vaccination, antibody levels in CPs with a primary series of AdV were comparable to those in HCWs, but nAb titers against the Omicron variant did not quantitatively increase in CPs with AdV vaccine as the primary series. The incidence and severity of adverse reactions post-vaccination were similar between CPs and HCWs.
Conclusion
CPs displayed delayed humoral immune response after SARS-CoV-2 vaccination. The booster dose elicited comparable bAb concentrations between CPs and HCWs, regardless of the primary vaccine type. Neutralization against the Omicron variant was not robustly elicited following the booster dose in some CPs, implying the need for additional interventions to protect them from COVID-19.

Citations

Citations to this article as recorded by

Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies
Giulio Olivieri, Donato Amodio, Emma Concetta Manno, Veronica Santilli, Nicola Cotugno, Paolo Palma
Vaccine.2025; 51: 126853. CrossRef
Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy
Jina Yun, Bora Kim, Hyuk Kim, Sung Hee Lim, Seong Hyeok Choi, Ji Youn Kim, Hyun Jung Kim, Seong Kyu Park
Clinics.2025; 80: 100757. CrossRef
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study
Hong-Hong Liu, Yunbo Xie, Bao-Peng Yang, Huan-Yue Wen, Peng-Hui Yang, Jin-E Lu, Yan Liu, Xi Chen, Meng-Meng Qu, Yang Zhang, Wei-Guo Hong, Yong-Gang Li, Junliang Fu, Fu-Sheng Wang
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis
Tiantian Hua, Ru Fan, Yang Fan, Feng Chen
Human Vaccines & Immunotherapeutics.2024;[Epub] CrossRef
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
Urska Janzic, Urska Bidovec-Stojkovic, Peter Korosec, Katja Mohorcic, Loredana Mrak, Marina Caks, Maja Ravnik, Erik Skof, Matija Rijavec
Vaccines.2023; 11(6): 1017. CrossRef
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients
Christopher W. Dukes, Marine Potez, Jeffrey Lancet, Barbara J. Kuter, Junmin Whiting, Qianxing Mo, Brett Leav, Haixing Wang, Julie S. Vanas, Christopher L. Cubitt, Kimberly Isaacs-Soriano, Kayoko Kennedy, Julie Rathwell, Julian Diaz Cobo, Wesley O’Nan, Br
Vaccines.2023; 12(1): 13. CrossRef

7,663 View
229 Download
6 Web of Science
6 Crossref

First
Prev
Page of 11
Next
Last

Search